UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 205

Sortiert nach

Pharmacokinetic Interactions Between Tegoprazan and the Combination of Clarithromycin, Amoxicillin and Bismuth in Healthy Chinese Subjects: An Open-Label, Single-Center, Multiple-Dosage, Self-Controlled, Phase I Trial

Clinical drug investigation, 2024-05, Vol.44 (5), p.343-355

2024

Link zum Volltext

Verfügbarkeit prüfen

Antibiomania: A Case Report of a Manic Episode Potentially Induced by the Interaction of Clarithromycin and Amoxicillin during H. Pylori Eradication Therapy

Actas espanolas de psiquiatria, 2024-02, Vol.52 (1), p.57

2024

Link zum Volltext

Verfügbarkeit prüfen

High‐dose dual therapy versus bismuth‐containing quadruple therapy for the eradication of Helicobacter pylori: A systematic review and meta‐analysis

Journal of digestive diseases, 2024-03, Vol.25 (3), p.163-175

2024

Link zum Volltext

Verfügbarkeit prüfen

Fourteen-day vonoprazan-based bismuth quadruple therapy for H. pylori eradication in an area with high clarithromycin and levofloxacin resistance: a prospective randomized study (VQ-HP trial)

Scientific reports, 2024-04, Vol.14 (1), p.8986-8986

2024

Link zum Volltext

Verfügbarkeit prüfen

Comparison of Helicobacter pylori eradication rates between 7 and 14 days of tailored therapy according to clarithromycin resistance test: A randomized, multicenter, non-inferiority study

Helicobacter (Cambridge, Mass.), 2024-05, Vol.29 (3), p.e13084-e13084

2024

Link zum Volltext

Verfügbarkeit prüfen

Effects of clarithromycin exposure on the growth of Microcystis aeruginosa and the production of algal dissolved organic matter

Aquatic toxicology, 2024-06, Vol.271, p.106918-106918, Article 106918

2024

Link zum Volltext

Verfügbarkeit prüfen

Vonoprazan-amoxicillin dual regimen with Saccharomyces boulardii as a rescue therapy for Helicobacter pylori : Current perspectives and implications

World journal of gastroenterology : WJG, 2024-03, Vol.30 (10), p.1280-1286

2024

Link zum Volltext

Verfügbarkeit prüfen

Comparison of vonoprazan-based dual therapy with vonoprazan-based bismuth quadruple therapy for treatment-naive patients with Helicobacter pylori infection: A propensity score matching analysis

Medicine (Baltimore), 2024-03, Vol.103 (10), p.e37476-e37476

2024

Link zum Volltext

Verfügbarkeit prüfen

Treatment of Helicobacter pylori with potassium competitive acid blockers: A systematic review and meta-analysis

World journal of gastroenterology : WJG, 2024-03, Vol.30 (9), p.1213-1223

2024

Link zum Volltext

Verfügbarkeit prüfen

Antibiotic prophylaxis for dental procedures

The Medical letter on drugs and therapeutics (English ed.), 2024-04, Vol.66 (1701), p.71-72

2024

Link zum Volltext

Verfügbarkeit prüfen

The effects of drug-drug interaction on linezolid pharmacokinetics: A systematic review

European journal of clinical pharmacology, 2024-06, Vol.80 (6), p.785-795

2024

Link zum Volltext

Verfügbarkeit prüfen

Equivalence Trial of the Non-Bismuth 10-Day Concomitant and 14-Day Hybrid Therapies for Helicobacter pylori Eradication in High Clarithromycin Resistance Areas

Antibiotics (Basel), 2024-03, Vol.13 (3), p.280

2024

Link zum Volltext

Verfügbarkeit prüfen

Comparison of the Efficacy of 12-day Concomitant Quadruple Therapy versus 14-day High dose Dual Therapy as a First-line H. pylori Eradication Regimen

대한소화기학회지, 2024, 83(4), , pp.150-156

2024

Link zum Volltext

Verfügbarkeit prüfen

Significance of early diagnosis and surgical management in treating Mycobacterium immunogenum-related pyogenic extensor tenosynovitis: a case report

BMC infectious diseases, 2024-04, Vol.24 (1), p.395-395

2024

Link zum Volltext

Verfügbarkeit prüfen

Equivalence Trial of the Non-Bismuth 10-Day Concomitant and 14-Day Hybrid Therapies for IHelicobacter pylori/I Eradication in High Clarithromycin Resistance Areas

Antibiotics (Basel), 2024-03, Vol.13 (3)

2024

Link zum Volltext

Verfügbarkeit prüfen

Refractoriness to anti‐Helicobacter pylori treatment attributed to phenotypic resistance patterns in patients with gastroduodenopathy in Guayaquil‐Ecuador

Helicobacter (Cambridge, Mass.), 2024-03, Vol.29 (2), p.e13060-n/a

2024

Link zum Volltext

Verfügbarkeit prüfen

Architectural design of 2D covalent organic frameworks (COFs) for pharmaceutical pollutant removal

npj clean water, 2024-12, Vol.7 (1), p.31-15

2024

Link zum Volltext

Verfügbarkeit prüfen

Concomitant and Bismuth Quadruple Therapy for Helicobacter pylori Eradication in Southern Italy: Preliminary Data from a Randomized Clinical Trial

Antibiotics (Basel), 2024-04, Vol.13 (4), p.348

2024

Link zum Volltext

Verfügbarkeit prüfen

Variables associated with antibiotic treatment tolerance in patients with Mycobacterium avium complex pulmonary disease

Respiratory research, 2024-03, Vol.25 (1), p.123-123

2024

Link zum Volltext

Verfügbarkeit prüfen

Role of compliance in Helicobacter pylori eradication treatment: Results of the European Registry on H. pylori management

United European gastroenterology journal, 2024-04

2024

Link zum Volltext

Verfügbarkeit prüfen

Application of furazolidone in Helicobacter pylori infection eradication

Journal of digestive diseases, 2024-03, Vol.25 (3), p.148-155

2024

Link zum Volltext

Verfügbarkeit prüfen

Amoxicillin, gemifloxacin and rabeprazole, as first-line Helicobacter pylori therapy in clinical practice: A pilot study

Medicine (Baltimore), 2024-05, Vol.103 (18), p.e38012-e38012

2024

Link zum Volltext

Verfügbarkeit prüfen

Relationships between acute generalized eruptive pustulosis, age, sex, primary disease, and prescription medications: Further analysis of the Japanese Adverse Drug Event Report database

Heliyon, 2024-04, Vol.10 (7), p.e27800-e27800, Article e27800

2024

Link zum Volltext

Verfügbarkeit prüfen

Pharmacotherapeutic Considerations in the Treatment of Nontuberculous Mycobacterial Infections: A Primer for Clinicians

Open forum infectious diseases, 2024-04, Vol.11 (4), p.ofae128-ofae128

2024

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 205

Suche als RSS-Feed

Aktive Filter

Neu hinzugefügt... seit 90 Tagen

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(167)
Mit Volltextzugriff
(165)

Publikationsform

2 weitere anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(112)
Life Sciences & Biomedicine
(103)
Humans
(78)
Antibiotics
(66)
Infections
(35)
Drug Resistance
(34)
Patients
(34)
Microbiology
(30)
Helicobacter Pylori
(29)
Pharmacology & Pharmacy
(29)
Health Aspects
(27)
Antimicrobial Agents
(24)
Medicine
(23)
Infectious Diseases
(22)
Anti-Bacterial Agents - Therapeutic Use
(21)
Bacteria
(21)
Female
(21)
Drug Therapy, Combination
(19)
Metronidazole
(19)
Drug Dosages
(18)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 7 Tagen
(18)
... seit 30 Tagen
(52)

Menü

Weitere Dienste

Einstellungen

Pharmacokinetic Interactions Between Tegoprazan and the Combination of Clarithromycin, Amoxicillin and Bismuth in Healthy Chinese Subjects: An Open-Label, Single-Center, Multiple-Dosage, Self-Controlled, Phase I Trial

Antibiomania: A Case Report of a Manic Episode Potentially Induced by the Interaction of Clarithromycin and Amoxicillin during H. Pylori Eradication Therapy

High‐dose dual therapy versus bismuth‐containing quadruple therapy for the eradication of Helicobacter pylori: A systematic review and meta‐analysis

Fourteen-day vonoprazan-based bismuth quadruple therapy for H. pylori eradication in an area with high clarithromycin and levofloxacin resistance: a prospective randomized study (VQ-HP trial)

Comparison of Helicobacter pylori eradication rates between 7 and 14 days of tailored therapy according to clarithromycin resistance test: A randomized, multicenter, non-inferiority study

Effects of clarithromycin exposure on the growth of Microcystis aeruginosa and the production of algal dissolved organic matter

Vonoprazan-amoxicillin dual regimen with Saccharomyces boulardii as a rescue therapy for Helicobacter pylori : Current perspectives and implications

Comparison of vonoprazan-based dual therapy with vonoprazan-based bismuth quadruple therapy for treatment-naive patients with Helicobacter pylori infection: A propensity score matching analysis

Treatment of Helicobacter pylori with potassium competitive acid blockers: A systematic review and meta-analysis

Antibiotic prophylaxis for dental procedures

The effects of drug-drug interaction on linezolid pharmacokinetics: A systematic review

Equivalence Trial of the Non-Bismuth 10-Day Concomitant and 14-Day Hybrid Therapies for Helicobacter pylori Eradication in High Clarithromycin Resistance Areas

Comparison of the Efficacy of 12-day Concomitant Quadruple Therapy versus 14-day High dose Dual Therapy as a First-line H. pylori Eradication Regimen

14‐day tailored PCR‐guided triple therapy versus 14‐day non‐Bismuth concomitant quadruple therapy for Helicobacter pylori eradication: A multicenter, open‐label randomized noninferiority controlled trial

Significance of early diagnosis and surgical management in treating Mycobacterium immunogenum-related pyogenic extensor tenosynovitis: a case report

Equivalence Trial of the Non-Bismuth 10-Day Concomitant and 14-Day Hybrid Therapies for IHelicobacter pylori/I Eradication in High Clarithromycin Resistance Areas

Refractoriness to anti‐Helicobacter pylori treatment attributed to phenotypic resistance patterns in patients with gastroduodenopathy in Guayaquil‐Ecuador

Architectural design of 2D covalent organic frameworks (COFs) for pharmaceutical pollutant removal

Concomitant and Bismuth Quadruple Therapy for Helicobacter pylori Eradication in Southern Italy: Preliminary Data from a Randomized Clinical Trial

Variables associated with antibiotic treatment tolerance in patients with Mycobacterium avium complex pulmonary disease

Role of compliance in Helicobacter pylori eradication treatment: Results of the European Registry on H. pylori management

Application of furazolidone in Helicobacter pylori infection eradication

Amoxicillin, gemifloxacin and rabeprazole, as first-line Helicobacter pylori therapy in clinical practice: A pilot study

Relationships between acute generalized eruptive pustulosis, age, sex, primary disease, and prescription medications: Further analysis of the Japanese Adverse Drug Event Report database

Pharmacotherapeutic Considerations in the Treatment of Nontuberculous Mycobacterial Infections: A Primer for Clinicians

Aktive Filter

Suchergebnisse filtern